Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 6/2014

01-06-2014 | Letter to the Editor

The beneficial effect of leflunomide on systemic lupus erythematosus: the role of Tregs repopulation?

Comment on: Leflunomide: friend or foe for systemic lupus erythematosus? Rheumatol Int 2013, 33(2):273–6

Author: Jae Il Shin

Published in: Rheumatology International | Issue 6/2014

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Wu GC, Xu XD, Huang Q et al (2013) Leflunomide: friend or foe for systemic lupus erythematosus? Rheumatol Int 33:273–276PubMedCrossRef
2.
3.
Wang TY, Li J, Li CY, et al (2010) Leflunomide induces immunosuppression in collagen-induced arthritis rats by upregulating CD4+CD25+ regulatory T cells. Can J Physiol Pharmacol 88:45–53
4.
Baban B, Liu JY, Mozaffari MS (2012) Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney: role of Tregs and stem cells. Am J Physiol Regul Integr Comp Physiol 303:R1136–R1146PubMedCrossRef
Metadata
Title
The beneficial effect of leflunomide on systemic lupus erythematosus: the role of Tregs repopulation?
Comment on: Leflunomide: friend or foe for systemic lupus erythematosus? Rheumatol Int 2013, 33(2):273–6
Author
Jae Il Shin
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 6/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2795-z

Other articles of this Issue 6/2014

Rheumatology International 6/2014 Go to the issue

Original Article

Are there differences in quality of life, symptomatology and functional capacity among different obesity classes in women with fibromyalgia? The al-Ándalus project

Letter to the Editor

Anti-cyclic citrullinated peptide (anti-CCP) antibodies with brucellosis

Short Communication

Mediterranean diet intervention for patients with hyperuricemia: a pilot study

Original Article

Candidate’s single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in ankylosing spondylitis

Original Article

Clinical management of patients with hip and knee osteoarthritis: patient satisfaction with treatment switch

Short Communication

Adult-onset Still’s disease and pregnancy: about ten cases and review of the literature
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits